AgomAb Therapeutics (NASDAQ:AGMB) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of AgomAb Therapeutics (NASDAQ:AGMB) from a sell rating to a hold rating in a research note issued to investors on Saturday morning,Wall Street Zen reports.

A number of other brokerages have also issued reports on AGMB. Piper Sandler started coverage on shares of AgomAb Therapeutics in a research note on Tuesday, August 25th. They set an “overweight” rating and a $60.00 target price for the company. HC Wainwright reaffirmed a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday. Cantor Fitzgerald started coverage on shares of AgomAb Therapeutics in a report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, B. Riley Financial initiated coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective for the company. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, AgomAb Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $37.50.

AgomAb Therapeutics Trading Up 0.7%

Shares of NASDAQ AGMB opened at $12.17 on Friday. AgomAb Therapeutics has a fifty-two week low of $8.75 and a fifty-two week high of $17.82. The business’s 50 day moving average price is $13.33 and its 200-day moving average price is $12.36.

AgomAb Therapeutics (NASDAQ:AGMB) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Analysts forecast that AgomAb Therapeutics will post -1.76 earnings per share for the current year.

About AgomAb Therapeutics

AgomAb Therapeutics N.V. (NASDAQ: AGMB) is a clinical-stage biopharmaceutical company developing medicines for diseases involving tissue damage, fibrosis and impaired regeneration. The company’s approach includes modulating biological pathways that influence tissue repair and remodeling, with the goal of addressing conditions with significant unmet medical needs.

AgomAb’s lead clinical program is AGMB-129, an oral, gut-restricted inhibitor of activin receptor-like kinase 5 (ALK5), a receptor involved in transforming growth factor beta signaling.